Terumo Corporation (TYO:4543)
Japan · Delayed Price · Currency is JPY | Market Cap | 3.03T -23.3% |
| Revenue (ttm) | 1.10T +8.3% |
| Net Income | 127.90B +2.2% |
| EPS | 86.69 +2.8% |
| Shares Out | 1.48B |
| PE Ratio | 23.71 |
| Forward PE | 20.00 |
| Dividend | 30.00 (1.48%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 3,992,900 |
| Average Volume | 4,609,610 |
| Open | 2,042.00 |
| Previous Close | 2,025.00 |
| Day's Range | 2,031.50 - 2,057.50 |
| 52-Week Range | 1,900.00 - 2,842.50 |
| Beta | 0.22 |
| RSI | 41.57 |
| Earnings Date | May 15, 2026 |
About Terumo
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. It operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems,... [Read more]
Financial Performance
In fiscal year 2025, Terumo's revenue was 1.04 trillion, an increase of 12.40% compared to the previous year's 921.86 billion. Earnings were 116.98 billion, an increase of 9.97%.
Financial StatementsNews
Terumo Earnings Call Transcript: Q3 2026
Record-high revenue and profits were achieved, driven by strong North American demand and effective pricing strategies that offset tariffs and FX headwinds. Acquisitions of Leverkusen Plant and OrganOx contributed to results, and the company remains on track to meet GS 2026 targets.
Terumo Transcript: 44th Annual J.P. Morgan Healthcare Conference
Global sales growth is driven by innovation in vascular access, CDMO, and blood technologies, with a focus on margin expansion and strategic M&A. OrganOx acquisition is expected to deliver high double-digit growth and significant market impact, while U.S., Japan, China, and India remain key markets.
Terumo Earnings Call Transcript: Q2 2026
Record first-half revenue and profits were achieved, driven by strong North American demand, pricing measures, and cost control. Full-year guidance was revised upward, with strategic investments and the Organox acquisition expected to fuel further growth.
OrganOx Completes Acquisition by Terumo Corporation to Advance the Future of Organ Transplantation
OXFORD, England and MADISON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- OrganOx Ltd.
Terumo Transcript: M&A Announcement
The acquisition of OrganOx for $1.5 billion enables entry into the high-growth organ transplantation market, leveraging innovative NMP technology to address unmet needs and expand into new domains. Synergies, cost advantages, and a strong strategic fit are expected to drive long-term growth.
Terumo Earnings Call Transcript: Q1 2026
Preparations for the Lacanbi auto injector launch are progressing, with cardiovascular growth led by volume and sustainable price increases. Significant compensation was received for a prior project cancellation, and China neuro sales rose due to VBP volume commitments.
Terumo Earnings Call Transcript: Q4 2025
Fiscal 2024 saw record revenue, profit, and free cash flow, driven by global demand and strategic restructuring. Outlook for 2025 is strong, with further margin improvement and global CDMO expansion, though U.S. tariffs pose a risk.
Terumo Earnings Call Transcript: Q3 2025
Record revenue and profit highs were achieved, driven by strong U.S. and global demand, effective pricing, and favorable forex. One-time restructuring and impairment costs were recorded, but underlying business momentum remains robust, with steady progress toward full-year targets.
Terumo Earnings Call Transcript: Q2 2025
Record half-year highs in sales, profits, and free cash flow were achieved, driven by strong demand, cost control, and favorable FX. Full-year guidance was raised, with innovation and expansion into the venous intervention market highlighted as key growth drivers.
Terumo Earnings Call Transcript: Q1 2025
Record quarterly highs in revenue and profit were achieved, driven by strong demand, pricing measures, and favorable exchange rates. All segments and regions posted robust growth, with continued margin improvement and cautious guidance maintained amid macroeconomic uncertainties.
Terumo Earnings Call Transcript: Q4 2024
Terumo Earnings Call Transcript: Q3 2024
Terumo Earnings Call Transcript: Q2 2024
IceCure Medical Continues to Experience Growing Global Interest in ProSense: Featured at the 16th Thai Breast Symposium
Professor Eisuke Fukuma, who has performed over 600 ProSense breast cancer cryoablation procedures, led a cryoablation symposium with ProSense IceCure joined its exclusive regional distributor, Terumo...